Novel Cardioprotective Properties of Asparagus racemosus (Shatavari)

Dyslipidemia and cardiovascular diseases (CVDs) continue to be important issues in global health; thus, finding better, safer treatments is crucial. Promising as a natural substitute for traditional lipid-regulating medications, the famous Ayurvedic herb Asparagus racemosus (Shatavari) has shown substantial cardioprotective and lipid-lowering properties. The anti-inflammatory, antioxidant, nitric oxide–modulating, and cholesterol biosynthesis–inhibiting actions of Shatavari are due to its abundance of bioactive chemicals, including saponins, flavonoids, alkaloids, and polyphenols. By influencing lipid metabolism and important enzyme pathways like HMG-CoA reductase and LCAT, Shatavari lowers total cholesterol, triglyceride, and LDL levels while increasing HDL levels, according to both experimental and preclinical research. Atherosclerosis prevention, endothelial function improvement, and protection against ischemia-reperfusion injury are all aspects of its cardioprotective properties. To confirm its effectiveness and safety in controlling dyslipidemia and cardiovascular disorders, large-scale clinical trials are required, even if early human investigations show promising results. Recent developments in formulation tactics, such as delivery systems based on nanoparticles and polyherbal combinations, have the ability to enhance the bioavailability and therapeutic effect of Shatavari. To make it more accessible in mainstream medicine, though, issues like standardization, quality control, and regulatory clearance need to be resolved. This chapter offers a thorough analysis of Shatavari’s cardioprotective and lipid-lowering effects, showcasing its possible involvement in the creation of pharmacological and nutraceutical therapies for heart health. In order to fully realize its therapeutic potential, future research should center on clinical validation, mechanistic studies, and new formulations.